for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Mercados

CanSino Biologics delivers COVID-19 vaccine to Mexico for late-stage trial

MEXICO CITY, Nov 3 (Reuters) - Mexico has received the first doses of a COVID-19 vaccine candidate from Chinese pharmaceutical company CanSino Biologics Inc. for a late stage-trial on between 10,000 and 15,000 volunteers, foreign minister Marcelo Ebrard said on Tuesday.

The country aims to vaccinate nearly all of its population against COVID-19 by the end of 2021 after reaching accords with pharmaceutical companies and the World Health Organization-backed COVAX plan.

“On October 30, the first doses were received to carry out phase three of clinical trials of the candidate vaccine from Cansino Bio,” Ebrard said at a news conference, adding that it would be one of the world’s largest COVID-19 clinical trials. (Reporting by Ana Isabel Martinez Writing by Stefanie Eschenbacher; Editing by Frank Jack Daniel)

Nuestros Estándares: Los principios Thomson Reuters.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up